← 홈

IL-13

10개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 10개
AntibodySHOTFDACuratedFDABiologicEli LillyApproved

lebrikizumab (Ebglyss, Lilly)

Atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 75상태 APPROVED
CGTBiologicstaleKite Pharma (a Gilead Company)Phase 1

CART-EGFR-IL13Ra2 Cells (CART-EGFR-IL13Ra2 Cells)

Glioblastoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 4상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

CART-EGFR-IL13Ra2 T cells (CART-EGFR-IL13Ra2 T cells)

Recurrent Glioblastoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleKubota Vision Inc.Phase 1

Dose level 1 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 15.4%임상시험 1상태 RECRUITING
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

Dose level 2 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleGlaxoSmithKlinePhase 1

Dose level 3 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 15.4%임상시험 1상태 RECRUITING
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

Dose level 4 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 1상태 RECRUITING
CGTBiologicstaleBristol-Myers SquibbPhase 1

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells)

Recurrent Glioblastoma; Refractory Glioblastoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleYang ZhangPhase 1

IL13Rα2 CAR-T (IL13Rα2 CAR-T)

Glioma · Glioma

#Glioma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleMing YangPhase 1

IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody (IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody)

Recurrent Malignant Glioma · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING